Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old

Authors not listed

Assistance Publique - Hôpitaux de Paris · 2021

Abstract

This study aims to evaluate the immunogenicity of Moderna mRNA-1273 vaccine in volunteers aged 65 years or more compared to volunteers aged 18-45 years, over 24 months duration. It will provide necessary data on the early immunological response to the vaccine and its evolution in quantitative and qualitative terms. This study will allow establishing how aging influences the response to the vaccine and help to adapt the vaccinal plan. For instance it will suggest the necessity of a vaccination booster.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2021). A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old. <em>Assistance Publique - Hôpitaux de Paris</em>. https://clinicaltrials.gov/study/NCT04748471
Vancouver
Anonymous. A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old. Assistance Publique - Hôpitaux de Paris. 2021.
BibTeX
@misc{anon2021APhase, title = {A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old}, author = {Anonymous}, journal = {Assistance Publique - Hôpitaux de Paris}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings